REFRACTORY MYCOSIS FUNGOIDES
Clinical trials for REFRACTORY MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for REFRACTORY MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose and see how well the combination works. About 38 adults with certain types of T-cell …
Matched conditions: REFRACTORY MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Cancer-killing virus plus immune booster shows promise for rare skin tumors
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard care. First, patients receive a virus-based therapy (talimogene laherparepvec) that infects and kills tumor cells. Then, they also get an immunotherapy …
Matched conditions: REFRACTORY MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy offers hope for patients with relapsed T-Cell lymphoma
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (a drug that blocks enzymes cancer cells need to grow), in people with peripheral T-cell lymphoma that has come back or stopped responding to tr…
Matched conditions: REFRACTORY MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC